Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Banking Press Releases.
Press releases published on October 25, 2025
Emirard Partners with SOBHA Realty to Expand Dubai Luxury Real Estate Access to Asian Investors
UAE-based Emirard, a DLD-licensed becomes the official gateway for Korean, Chinese, and Japanese investors to access premium Dubai property developments. DUBAI, DUBAI, UNITED ARAB EMIRATES, October 25, 2025 /EINPresswire.com/ -- Emirard, the UAE-based …
Conclusion of the Inaugural Private Capital Forum 2025 in Riyadh
Conclusion of the Inaugural Private Capital Forum 2025 in Riyadh RIYADH, SAUDI ARABIA, October 25, 2025 /EINPresswire.com/ -- The first edition of the Private Capital Forum 2025 concluded today in Riyadh, after two days of insightful discussions hosted …
Conclusion of the Inaugural Private Capital Forum 2025 in Riyadh
Conclusion of the Inaugural Private Capital Forum 2025 in Riyadh RIYADH, SAUDI ARABIA, October 25, 2025 /EINPresswire.com/ -- The first edition of the Private Capital Forum 2025 concluded today in Riyadh, after two days of insightful discussions hosted …
Affordable Living Trust Preparation Services Now Available Across California
Create your living trust in California for only $1200 — affordable, reliable, and designed to protect what matters most, without paying high attorney fees. COSTA MESA, CA, UNITED STATES, October 25, 2025 /EINPresswire.com/ -- California residents can …
Berry Releases Price Analysis and Forecast for BTC, ETH, XRP, and DOGE Amid Market Shifts
October 2025 — Cryptocurrency markets have shown mixed signals this week CHICAGO, IL, UNITED STATES, October 25, 2025 /EINPresswire.com/ -- Cryptocurrency markets have shown mixed signals this week，with Bitcoin (BTC) maintaining relative stability, …
#1 Texas Local Medicare Agent Doubles Client Base Amid 2026 Medicare Part D Disruptions
HOUSTON, TX, UNITED STATES, October 25, 2025 /EINPresswire.com/ -- As seniors face unprecedented changes in Medicare Part D driven by the Inflation Reduction Act of 2022, Rodney Powell, Texas’ top-rated Medicare agent on Medicare Agents Hub, is doubling …
RockToken Leads Digital Investment Awareness as JPMorgan Adopts Bitcoin Collateral
AUCKLAND, NEW ZEALAND, October 25, 2025 /EINPresswire.com/ -- PMorgan’s recent move to accept Bitcoin as collateral marks a historic milestone in institutional cryptocurrency adoption. This strategic shift highlights a powerful truth — digital asset …
VRA Investor News: If You Have Suffered Losses in Vera Bradley, Inc. (NASDAQ: VRA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Oct. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Vera Bradley, Inc. (NASDAQ: VRA) resulting from allegations that Vera …
ROSEN, A LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action – MLTX
NEW YORK, Oct. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “ …
Blazpay’s Crypto Presale Surges Past $840k with Less Than a Week Remaining Until the Next Phase
PANAMA CITY, Oct. 25, 2025 (GLOBE NEWSWIRE) -- The crypto market is buzzing as Blazpay’s Phase 2 Crypto Presale continues its rapid ascent, now 76% complete with over $843.6K raised. Priced at $0.0075 per BLAZ token, Blazpay’s Next Big Crypto Coin offers …
Zions Bancorporation Investor News: If You Have Suffered Losses in Zions Bancorporation, N.A. (NASDAQ: ZION, ZIONP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Oct. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zions Bancorporation, N.A. (NASDAQ: ZION, ZIONP) resulting from …
Missacc Announces Exclusive Halloween Week Promotion - 15% Discount on All Event Dresses
LOS ANGELES, CA, UNITED STATES, October 25, 2025 /EINPresswire.com/ -- Missacc, a leading online destination for event and formal dresses, today announced the launch of its Halloween Week Sale, offering customers 15% off sitewide for 72 hours only. The …
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
NEW YORK, Oct. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class …
AlphaTON Capital and Cyncado Therapeutics Share New Mesothelioma Data Supporting TT-4’s Path to First- Patient Dosing
Dover, DE, Oct. 25, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, today announced that a new poster is live at the AACR-NCI-EORTC …
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating …
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease Discussion of …
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a well-tolerated profile, consistent with …